CommentModelling the mortality of sickle cell disease in Africa
References (10)
- et al.
Observed and expected frequencies of structural hemoglobin variants in newborn screening surveys in Africa and the Middle East: deviations from Hardy-Weinberg equilibrium
Genet Med
(2016) - et al.
The epidemiology of sickle cell disease in children recruited in infancy in Kilifi, Kenya: a prospective cohort study
Lancet Glob Health
(2019) - et al.
Child mortality from sickle cell disease in Nigeria: a model-estimated, population-level analysis of data from the 2018 Demographic and Health Survey
Lancet Haematol
(2021) Natural selection. Philosophy of biology
(2007)- et al.
Consanguinity and inbreeding in health and disease in north African populations
Annu Rev Genomics Hum Genet
(2019)
There are more references available in the full text version of this article.
Cited by (1)
Effective therapies for sickle cell disease: are we there yet?
2022, Trends in GeneticsCitation Excerpt :The polymerization of HbS induces the formation of fragile, sticky, sickle-shaped RBCs, triggering a complex pathophysiology leading to the clinical manifestations of SCD [1,8]. In low-income regions where SCD is most prevalent, mainly Africa, at least half of SCD patients die before age 5 years [21–25]. Medical advances, including newborn screening, immunizations, antibiotics, and RBC transfusions with iron chelation, have greatly extended the lifespan of children with SCD in high-income countries [26].
© 2021 Elsevier Ltd. All rights reserved.